Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double blind placebo controlled pilot trial of memantine for cognitive impairment in multiple sclerosis.

Next Previous
Search
Trial Profile

Double blind placebo controlled pilot trial of memantine for cognitive impairment in multiple sclerosis.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Memantine (Primary)
  • Indications Cognition disorders; Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Jun 2010 Results have been published in Multiple Sclerosis.
    • 02 May 2009 Primary endpoint results presented at the 61st Annual Meeting of the American Academy of Neurology
    • 02 May 2009 Status change from recruiting to completed

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top